Research
Hormonal
Off-label use of semaglutide (Ozempic) for aesthetic weight loss in non-diabetic individuals causes therapeutic exclusion for Type 2 Diabetes patients due to supply shortages.
If you are using Ozempic off-label, be aware that your demand contributes to shortages for diabetics. Consider using approved alternatives like Wegovy if available, or prioritize lifestyle changes to reduce pressure on the supply chain for those who medically need it.
ModerateSupportsHIGH confidence
This phenomenon not only triggers therapeutic exclusion for diabetic patients, but also opens ethical discussions about drug distribution... The surge in Ozempic use makes it difficult for patients with diabetes to access the medicines they need because those who are obese are also taking Ozempic [13].
Why this rating
Based on observational data, prescription trends, and expert commentary rather than a controlled trial of exclusion.
Source
A Shift from Diabetic Clinical Therapy to Aesthetic Use: The Ozempic Phenomenon
Nadya Theresia Sibarani et al. · Journal of Biosciences and Medicines · 2026
DOI 10.4236/jbm.2026.142019
narrative_review
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Rapid weight loss induced by semaglutide causes 'Ozempic Face' and 'Ozempic Butt' due to the skin's inability to shrink at the same rate as fat loss.Moderate
- Discontinuation of semaglutide leads to significant weight regain (rebound effect) and psychological distress due to the dissipation of hormonal effects.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →